2245966-28-1
2245966-28-1
Chemical Structure
Daxdilimab
Synonym(s): MEDI7734; VIB7734
- CAS No.: 2245966-28-1
- Formula:N/A
- Molecular Weight:(144.38 kDa)
SMILES: [Daxdilimab]
Biological Activity: Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Daxdilimab | 97.82% | Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Patel S, et al. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021 Feb;7(2):e06158. [Content Brief]
- [2]. Retamozo S, et al. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opin Pharmacother. 2021 Dec;22(17):2359-2371. [Content Brief]
Keywords
